145 related articles for article (PubMed ID: 17262115)
21. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
Barry EV; Vrooman LM; Dahlberg SE; Neuberg DS; Asselin BL; Athale UH; Clavell LA; Larsen EC; Moghrabi A; Samson Y; Schorin MA; Cohen HJ; Lipshultz SE; Sallan SE; Silverman LB
J Clin Oncol; 2008 Mar; 26(7):1106-11. PubMed ID: 18309945
[TBL] [Abstract][Full Text] [Related]
22. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
23. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
24. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
Mladosievicova B; Foltinová A; Petrásová H; Bernadic M; Hulín I
Neoplasma; 2001; 48(1):61-5. PubMed ID: 11327539
[TBL] [Abstract][Full Text] [Related]
25. Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.
Van Tine BA; Hirbe AC; Oppelt P; Frith AE; Rathore R; Mitchell JD; Wan F; Berry S; Landeau M; Heberton GA; Gorcsan J; Huntjens PR; Soyama Y; Vader JM; Alvarez-Cardona JA; Zhang KW; Lenihan DJ; Krone RJ
Clin Cancer Res; 2021 Jul; 27(14):3854-3860. PubMed ID: 33766818
[TBL] [Abstract][Full Text] [Related]
26. [Echocardiographic assessment of circulation system in patients during and 3-5 years after all therapy in childhood].
Ostański M; Sońta-Jakimczyk D
Wiad Lek; 2002; 55(3-4):164-73. PubMed ID: 12182001
[TBL] [Abstract][Full Text] [Related]
27. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
28. Acute dosage with dexrazoxane, but not doxorubicin, is associated with increased rates of hepatic protein synthesis in vivo.
Zima T; Tesar V; Sherwood R; Sood A; Au LC; Richardson PJ; Preedy VR
Toxicol Pathol; 2001; 29(6):591-9. PubMed ID: 11794374
[TBL] [Abstract][Full Text] [Related]
29. Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.
FitzPatrick WM; Dervisis NG; Kitchell BE
Vet Comp Oncol; 2010 Dec; 8(4):273-82. PubMed ID: 21062409
[TBL] [Abstract][Full Text] [Related]
30. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
31. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
32. [Changes in left ventricular function during chemotherapy with doxorubicin].
Elbl L; Chaloupka V; Vásová I; Kiss I; Jancík J; Vorlícek J; Navrátil M
Vnitr Lek; 1999 Jul; 45(7):395-402. PubMed ID: 11045157
[TBL] [Abstract][Full Text] [Related]
33. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.
Tahover E; Segal A; Isacson R; Rosengarten O; Grenader T; Gips M; Cherny N; Heching NI; Mesika L; Catane R; Gabizon A
Anticancer Drugs; 2017 Aug; 28(7):787-794. PubMed ID: 28562379
[TBL] [Abstract][Full Text] [Related]
34. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
35. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
[TBL] [Abstract][Full Text] [Related]
36. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
37. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
[TBL] [Abstract][Full Text] [Related]
38. Dynamic stress echocardiography in asymptomatic patients who received chemotherapy in childhood because of a malignant disease.
Elbl L; Hrstkova H; Chaloupka V; Michalek J
Kardiol Pol; 2003 Mar; 58(3):190-6. PubMed ID: 14513093
[TBL] [Abstract][Full Text] [Related]
39. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
Vrooman LM; Neuberg DS; Stevenson KE; Asselin BL; Athale UH; Clavell L; Cole PD; Kelly KM; Larsen EC; Laverdière C; Michon B; Schorin M; Schwartz CL; Cohen HJ; Lipshultz SE; Silverman LB; Sallan SE
Eur J Cancer; 2011 Jun; 47(9):1373-9. PubMed ID: 21514146
[TBL] [Abstract][Full Text] [Related]
40. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
Stöhr W; Paulides M; Brecht I; Kremers A; Treuner J; Langer T; Beck JD;
J Cancer Res Clin Oncol; 2006 Jan; 132(1):35-40. PubMed ID: 16205946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
